The in vitro findings were consistent across the agents tested, with a single cell line with an activating KIT mutation (the AML cell line Kasumi-1) showing in vitro sensitivity at 1–2 log lower concentrations than the remaining cell lines (Keir et al., 2010; Maris et al., 2008; Morton et al., 2012; Smith et al., 2013). This evidence concerns the gene KIT and acute myeloid leukemia.